Involvement of endothelial and non-endothelial mechanisms in the vasoconstrictor activity of Aβ peptide

Alzheimer's Reports

Volumn 2, Issue 2, 1999, Pages 105-112

  Poliviou, Helen ^a   Khalil, Zeinab ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001090514     PISSN: 14616130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. 2 metabolism by catalase. Free Radical Med Biol 7, 485-490.
2. Crawford F, Suo Z, Fang C and Mullan M (1997). Beta-amyloid peptides and enhancement of vasoconstriction by endothelin-1. Ann N Y Acad Sci 826, 461-462.
3. Gabuzda D, Busciglio J, Chen L et al. (1994). Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269, 13623-13628
4. Giokarini T, Bonafini L, Shearman M et al. (1997). Beta-amyloid (Abeta 1-40)-evoked changes in vascular reactivity are mediated via an endothelium-specific mechanism, studies using rabbit isolated aorta [in Process Citation]. Ann N Y Acad Sci 826, 475-478.
5. Grammas P, Botchlet T, Moore P and Weigel P (1997). Production of neurotoxic factors by brain endothelium in AD. Ann NY Acad Sci 826, 47-55.
6. 2+ pump. Am J Physiol 269, C546-C553.
7. Hachinski V and Munoz DG (1997). Cerebrovascular Pathology in Alzheimer's disease, cause, effect or epiphenomenon. Ann NY Acad Sci 826, 1-7.
8. Hajimohammadreza I, Anderson V, Cavanagh JC et al. (1994). Beta-Amyloid precursor protein fragments and lysosomal dense bodies are found in rat brain neurons after ventricular infusion of leupeptin. Brain Res 640, 25-32.
9. Harris M, Carney J, Cole P et al. (1995). Beta-amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes, implications for Alzheimer's disease. NeuroReport 6, 1875-1879.
10. Hensley K, Aksenova M, Carney J et al. (1995a). Amyloid beta-peptide spin trapping I. Peptide enzyme toxicity is related to free radical spin trap reactivity. NeuroReport 6, 489-492.
11. Hensley K, Aksenova M, Carney J et al. (1995b). Amyloid beta-peptide spin trapping II. Evidence for decomposition of the PBN spin adduct. NeuroReport 6, 493-496.
12. Hensley K, Carney J, Mattson M et al. (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide, relevance to Alzheimer disease. Proc Natl Acad Sci USA 91, 3270-3274.
13. Huang Z (1994). Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265, 1883-1885.
14. Khalil Z, Chen H and Helme R (1996). Mechanisms underlying the vascular activity of beta-amyloid protein fragment (beta A(4)25-35) at the level of skin microvasculature. Brain Res 736, 206-216.
15. Khalil Z, Sanderson K, Isberg P et al. (1994). Beta A4(25-35) modulates substance P effect on rat skin microvasculature in aged rats, pharmacological manipulation using SEC-receptor ligands. Brain Res 651, 227-235.
16. Marcus DL and Freedman FML (1997). Microvessels from patients with Alzheimer's disease have altered glucose metabolism. Ann NY Acad Sci 826, 248-253.
17. Mecocci P, MacGrarvey U and Beal M (1994). Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36, 747-751.
18. Naslund J, Schierhorn A, Hellman U et al. (1994). Relative abundance of Alzheimer Aβ-amyloid peptide variants in Alzheimer's disease and normal aging. Proc Natl Acad Sci USA 91, 8378-8382.
19. Omar H, Cherry P, Mortelliti M et al. (1991). Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. Circ Res 69, 601-608.
20. Packer C, Rhoades R Impaired pulmonary vascular smooth muscle function in human lung Lung Biol Health Dis 1992; 60, 227-262.
21. Pappolla M, Chyan Y, Omar R et al. (1998). Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease, a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152, 871-877.
22. Pettegrew JW, Panchalingam K, McClure RJ and Stanley JA (1997). MR spectroscopic changes in Alzheimer's disease Ann NY AcadSci 826, 282-386.
23. Pike C, Overman M and Cotman C (1995a). Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270, 23895-23898.
24. Pike C, Walencewicz-Wasserman A, Kosmoski J et al. (1995b). Structure-activity analyses of β-amyloid peptides, Contributions of the β25-35 region to aggregation and neurotoxicity J Neurochem 64, 253-265.
25. Poliviou H and Khalil Z (1998a). β-amyloid protein fragments modulate the vascular activity of Substance P at the level of the microvasculature. Alz Reports 1, 33-40.
26. Poliviou H and Khalil Z (1998b). β-amyloid protein modulates the vascular activity of acetylcholine at the level of the skin microvasculature. Alz Reports 1, 233-239.
27. Price J, Sutton E, Hellermann A and Thomas T (1997). Betaamyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res 19, 534-538.
28. Rocca W, Amaducci L and Schoenberg B (1986). Epidemiology of clinically diagnosed Alzheimer's disease. Ann Neurol 19, 415-424.
29. Smith C, Carney J and Stake-Reed P (1991). Excess brain oxidation and enzyme dysfunction in normal aging and Alzheimer's disease. Proc Natl Acad Sci USA 88, 10540-10543.
30. Sparks D (1997). Coronary artery disease, hypertension, ApoE, and cholesterol, a link to Alzheimer's disease? Ann N Y Acad Sci 826, 128-146.
31. Strittmatter W, Saunders A, Schmechel D et al. (1993). Apolipoprotein E, high-affinity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977-19781.
32. Subbarao K, Richardson J and Ang L (1990). Autopsy samples of Alzheimer's cortex show increases peroxidation in vitro. J Neurochem 55, 342-345.
33. Terzi E, Holzemann G and Seelig J (1994). Alzheimer beta-amyloid peptide 25-35, electrostatic interactions with phospholipid membranes. Biochemistry 33, 7434-7441.
34. Thomas T, McLendon C, Sutton E and Thomas G (1997a). Beta-Amyloid-induced cerebrovascular endothelial dysfunction. Ann N Y Acad Sci 826, 447-51.
35. Thomas T, McLendon C, Sutton E and Thomas G (1997b). Cerebrovascular endothelial dysfunction mediated by beta-amyloid. NeuroReport 8, 1387-91.
36. Thomas T, Sutton E, Hellermann A and Price J (1997c). Beta-amyloid-induced coronary artery vasoactivity and endothelial damage. J Cardiovasc Pharmacol 30, 517-22.